CURE has an FDA-registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform which includes CUREfilm®, one of the most advanced oral thin films on the market today; CUREpods™ a novel chewable delivery system and other more traditional dose forms that use advanced encapsulation technology. CUREform’s combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURE also holds the NSF® cGMP certification for manufacturing dietary supplements.
CURE’s clinical pipeline includes CUREfilm® Blue (sildenafil to treat erectile dysfunction), and CUREfilm® Canna (THC and CBD) each designed to optimize the pharmacokinetic profile of the medicine.
CURE partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S.A, Canada, Israel, and other markets.
Cure Pharmaceutical Corporation was founded in July 2011 and is a wholly-owned subsidiary of Cure Pharmaceutical Holding Corp, a public company.
1620 Beacon Place
Oxnard, CA 93033
We are positioned to advance numerous therapeutic categories, including pharmaceutical cannabis.
Our Investor Presentation
CURE Pharmaceutical Investor
Video Webcast | Dec. 17 2020
CBD, Cannabis and the Cannabiz
In the news
Fiscal Year 2020 Highlights: Generated dramatic growth in total and pro forma revenue Released positive clinical data on its patented drug delivery technology and received new certifications at its research facility Acquired and expanded consumer wellness subsidiary...
CURE Pharmaceutical Launches Psychedelic Oral Film Program Targeting the Treatment of Mental Health Disorders
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched a new initiative for the clinical development of psychedelic compounds...
CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched two new clinical development programs and added new corresponding...
CURE Pharmaceutical’s Subsidiary Sera Labs Launches National Television, Radio & Digital Advertising Campaign for Nutri-Strips Sleep A.S.A.P.
Sleep A.S.A.P. provides proof of concept and monetization for CURE's patented oral thin-film technology LOS ANGELES & OXNARD, Calif. - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a technology focused, vertically integrated drug...
CURE Pharmaceutical Announces the Initiation of Clinical Trials for Erectile Dysfunction Product CUREfilm Blue™
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced this week's start of...
OXNARD, Calif. - CURE Pharmaceutical Holdings ("CURE" or the "Company") (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, announced today updates and additions to its Board of Directors. After...
Board of Directors
Chief Executive Officer, Director
Chief Financial Officer
Chief Strategic Officer and Director; CEO of Wholly owned subsidiary, The Sera Labs
Chief Scientific Officer
Chief Accounting Officer
Chief Business Officer
Vice President of Quality and Compliance Systems
Chairman of the Board
Chief Executive Officer, Director
Chief Strategic Officer and Director, CEO of Wholly owned subsidiary, The Sera Labs.
(805) 410-9962 ext. 4
805 3rd Avenue #1430
New York, NY 10022
10100 Santa Monica Blvd., 8th Fl.
Los Angeles, CA 90067